The U.S. Senate recently passed a bill with the intent of lowering drug prices by capping the number of patents that can be asserted in cases involving biosimilars. However, legal practitioners indicate that the bill’s numerous exceptions render it unlikely to significantly impact litigation or consumer costs. These exceptions, they argue, provide ample leeway for pharmaceutical companies to maneuver around the patent limitations, thereby dampening the bill’s effectiveness.
For further details on the potential implications of this legislation, please visit the original article.